Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NVO

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes

Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes

Novo Nordisk A/S (NYSE:NVO) has announced topline results from Phase 3a ONWARDS 2 trial, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs. insulin degludec. The study included 526 people with type 2 diabetes switching from daily insulin. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at…

5 Surging Mega-Cap Stocks to Add to Your Watchlist

5 Surging Mega-Cap Stocks to Add to Your Watchlist

The stock market has been experiencing high volatility due to various economic and geopolitical factors. But under these uncertain market conditions investors could add quality mega-cap stocks Novo Nordisk (NVO), Shell (SHEL), Eli Lilly (LLY), Novartis (NVS), and Costco (COST) to their watchlists. Mega-cap stocks are known to endure harsh…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

If You Invested $100 In Novo Nordisk 10 Years Ago, Here's How Much You Would Have Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

Why Novo Nordisk Shares Are Trading Higher Today

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

2 Top Pharmaceutical Stocks Down More Than 5% Year-to-Date to Buy Now

2 Top Pharmaceutical Stocks Down More Than 5% Year-to-Date to Buy Now

Despite logistical hindrances, the pharmaceutical industry has registered substantial growth over the past month, thanks to impressive innovation in the medical field and rapid technology integration. So, we think it could be wise to scoop up fundamentally sound pharmaceutical stocks Eli Lilly (LLY) and Novo Nordisk (NVO) on the dip…

3 Diabetes Stocks That are Better Investments Than Senseonics

3 Diabetes Stocks That are Better Investments Than Senseonics

Despite the ongoing global public health crisis, fundamentally-sound companies focused on diabetic treatments are seemingly unfazed. So, given Senseonics' (SENS) relative overvaluation and bleak growth prospects, we think it could be wise to bet on diabetes stocks Novo Nordisk (NVO), Eli Lilly (LLY), and Abbott Laboratories (ABT). Let’s discuss.

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S (NYSE: NVO)

1 … 3 4 5 6

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Abbott Laboratories

BristolMyers Squibb Company

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

359,664 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play